Finally, all three of the currently available anti-VEGF drugs Bevacizumab (AvastinTM), Ranibizumab (LucentisTM) and Aflibercept (EyleaTM) are also proven first-line therapies for n-AMD and are extensively used worldwide for the treatment of the VEGF-driven complication [18] of choroidal neovascularisation (CNV) [19, 20]. This evidence concerns the gene VEGFA and age-related macular degeneration.